First Patient Dosed In Crinetics' Pivotal Phase 3 Trial Of Atumelnant For CAH

Crinetics Pharmaceuticals has dosed the first patient in the pivotal Phase 3 CALM‑CAH trial of Atumelnant, an oral ACTH‑receptor antagonist for classic congenital adrenal hyperplasia that showed rapid, sustained biomarker improvements and reduced steroid dependence in Phase 2; the drug has U.S. FDA Orphan Drug designation and aims to normalize adrenal androgens while lowering glucocorticoid exposure. Near‑term catalysts include pediatric BALANCE‑CAH enrollment expected in Q4 2025, glucocorticoid‑reduction and 13‑week open‑label extension data in early 2026, and planning for a Phase 2/3 in ACTH‑dependent Cushing’s in H1 2026, while the company also advanced CRN09682 into first‑patient dosing. Crinetics ended September 30, 2025 with $1.1 billion in cash—projected to fund operations into 2029—and its shares have traded in a $24.10–$56.53 range, closing at $49.31 (+2.6%) before an overnight move to $48.20 (‑2.5%).

Analysis

Crinetics has dosed the first patient in the pivotal Phase 3 CALM-CAH trial of Atumelnant, an oral ACTH receptor antagonist for classic congenital adrenal hyperplasia, following Phase 2 results that showed rapid, sustained reductions in key disease biomarkers and reduced reliance on high‑dose glucocorticoids. The drug's once‑daily oral formulation and recent U.S. FDA Orphan Drug designation enhance its clinical and commercial profile relative to current steroid‑based regimens.

Near‑term catalysts are well defined: pediatric BALANCE‑CAH enrollment targeted for Q4 2025, glucocorticoid‑reduction data from Cohort 4 and 13‑week open‑label extension data expected in early 2026, and planning for a Phase 2/3 in ACTH‑dependent Cushing's in H1 2026; CRN09682 entered first‑patient dosing in December 2025. Management reports $1.1 billion in cash as of September 30, 2025, sufficient to fund operations into 2029, which reduces immediate dilution risk and supports execution of the stated development plan.

The stock is trading with noticeable volatility within a $24.10–$56.53 range and moved from a $49.31 close (+2.60%) to $48.20 overnight (-2.52%), reflecting binary sentiment around clinical catalysts. The Phase 3 initiation materially de‑risks program progression but clinical outcomes, safety signals and regulatory review remain binary value drivers; positive Phase 3 or extension data would be a meaningful re‑rating, while failed or safety‑negative readouts would likely compress valuation rapidly.

Key Decisions for Investors

• Consider maintaining or modestly increasing exposure to CRNX to capture upside from the early‑2026 glucocorticoid‑reduction and 13‑week OLE readouts, while keeping position sizes limited given binary Phase 3 risk
• Monitor Cohort 4 glucocorticoid‑reduction data and the 13‑week open‑label extension as primary near‑term catalysts and treat clear steroid‑sparing efficacy and favorable safety as de‑risking events
• Use the reported $1.1 billion cash runway into 2029 to justify lower near‑term dilution risk, but demand clearer long‑term commercialization planning before adding material long‑term exposure
• Watch enrollment progress for BALANCE‑CAH and timing for the planned Cushing's Phase 2/3; any delays should temper upside expectations and may warrant reducing exposure
• Given the stock's wide trading range and recent intraday moves, consider downside protection such as hedges or stop limits ahead of binary clinical milestones